Activity and Safety of Cetuximab Plus Modified FOLFOXIRI Followed by Maintenance With Cetuximab or Bevacizumab for RAS and BRAF Wild-type Metastatic Colorectal Cancer A Randomized Phase 2 Clinical Trial
JAMA Oncol. doi:10.1001/jamaoncol.2017.5314 Published online February 15, 2018.

The PANDA study: a randomized phase II study of first-line FOLFOX plus panitumumab versus 5FU plus panitumumab in RAS and BRAF wild-type elderly metastatic colorectal cancer patients
BMC Cancer (2018) 18:98 DOI 10.1186/s12885-018-4001-x

Formation of an international intergroup to coordinate clinical trials in head and neck cancers: HNCIG
Oral Oncology 71 (2017) 180–183

Primary tumor sidedness and benefit from FOLFOXIRI plus bevacizumab as initial therapy for metastatic colorectal cancer. Retrospective analysis of the TRIBE trial by GONO
Annals of Oncology 0: 1–7, 2018 doi:10.1093/annonc/mdy140 Published online 20 April 2018

Differential histopathologic parameters in colorectal cancer liver metastases resected after triplets plus bevacizumab or cetuximab: a pooled analysis of five prospective trials
British Journal of Cancer https://doi.org/10.1038/s41416-018-0015-z

TRIPLETE: a randomised phase III study of modified FOLFOXIRI plus panitumumab versus mFOLFOX6 plus panitumumab as initial therapy for patients with unresectable RAS and BRAF wild-type metastatic colorectal cancer
Borelli B, et al. ESMO Open 2018;3:e000403. doi:10.1136/esmoopen-2018-000403

Rechallenge for Patients with RAS and BRAF Wild-Type metastatic colorectal cancer with acquired resistance to First-Line Cetuximab and Irinotecan
Cremolini C, et al. JAMA Oncol. doi:10.1001/jamaoncol.2018.5080